As Vyvanse generics bite, Takeda sets out on $900M restructuring planAs Vyvanse generics bite, Takeda sets out on $900M restructuring plan - FiercePharma fiercepharma.com Submitted by fiercepharma5012 on May 10, 2024 at 4:00 PM in business No comments 9